GBP101.24
1.27%
London, Apr 17, 05:42 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP101.24
-17.80 14.95% 1M
-17.27 14.58% 6M
-1.94 1.88% YTD
-5.17 4.86% 1Y
+2.41 2.43% 3Y
+30.25 42.60% 5Y
+66.57 192.04% 10Y
London, Closing price Thu, Apr 17 2025
-1.30 1.27%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP156.98b
Enterprise Value GBP176.73b
P/E (TTM) P/E ratio 28.45
EV/FCF (TTM) EV/FCF 21.97
EV/Sales (TTM) EV/Sales 4.18
P/S ratio (TTM) P/S ratio 3.71
P/B ratio (TTM) P/B ratio 4.82
Dividend yield 2.43%
Last dividend (FY24) GBP2.46
Revenue growth (TTM) Revenue growth 14.82%
Revenue (TTM) Revenue GBP42.31b
EBIT (operating result TTM) EBIT GBP8.54b
Free Cash Flow (TTM) Free Cash Flow GBP8.05b
Cash position GBP4.51b
EPS (TTM) EPS GBP3.56
P/E forward 20.74
P/S forward 3.57
EV/Sales forward 4.02
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

28x Buy
88%
4x Hold
13%

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

Buy
88%
Hold
13%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
42,307 42,307
15% 15%
100%
- Direct Costs 11,739 11,739
18% 18%
28%
30,568 30,568
14% 14%
72%
- Selling and Administrative Expenses 7,246 7,246
13% 13%
17%
- Research and Development Expense 9,556 9,556
16% 16%
23%
13,767 13,767
33% 33%
33%
- Depreciation and Amortization 5,225 5,225
20% 20%
12%
EBIT (Operating Income) EBIT 8,542 8,542
43% 43%
20%
Net Profit 5,515 5,515
15% 15%
13%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Positive
FXEmpire
about 6 hours ago
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Neutral
Seeking Alpha
one day ago
After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAPEX spending, inflation, and rising recession odds. European equities are relatively cheap, and despite structural issues, pockets of opportunities exist in high-growth areas and via re-arming Europ...
Negative
Reuters
6 days ago
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today